Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommy Rampling

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
The Lancet. Infectious Diseases|November 8, 2015
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trialMilagritos D Tapia, Samba O Sow, Kirsten E Lyke, et al.
The Lancet. Rheumatology|September 1, 2020
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort studyJessica J Manson, Colin Crooks, Meena Naja, et al.
The Lancet. Child & Adolescent Health|September 29, 2023
Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UKSema Mandal, Ruth Simmons, Georgina Ireland, et al.
The New England Journal of Medicine|January 29, 2015
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVAKatie Ewer, Tommy Rampling, Navin Venkatraman, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Nature|March 30, 2023
Genomic investigations of unexplained acute hepatitis in childrenSofia Morfopoulou, Sarah Buddle, Oscar Enrique Torres Montaguth, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The Lancet. Infectious Diseases|November 8, 2015
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trialMilagritos D Tapia, Samba O Sow, Kirsten E Lyke, et al.
The Lancet. Rheumatology|September 1, 2020
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort studyJessica J Manson, Colin Crooks, Meena Naja, et al.
The Lancet. Child & Adolescent Health|September 29, 2023
Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UKSema Mandal, Ruth Simmons, Georgina Ireland, et al.
The New England Journal of Medicine|January 29, 2015
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVAKatie Ewer, Tommy Rampling, Navin Venkatraman, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Nature|March 30, 2023
Genomic investigations of unexplained acute hepatitis in childrenSofia Morfopoulou, Sarah Buddle, Oscar Enrique Torres Montaguth, et al.
Pageof 5